Patents Assigned to Novo Nordisk
-
Publication number: 20240123159Abstract: 1. A drug delivery device for delivering a plurality of fixed doses of a medicament, wherein the drug delivery device comprises a needle magazine with a plurality of needle assemblies, a needle positioning mechanism, a drive mechanism for delivering a fixed dose of the plurality of fixed doses, in response to activation, an activation mechanism for activating the drive mechanism comprising a movable shield (110, 310), wherein the shield (110, 310) is adapted to activate the drive mechanism, in response moving the shield to the proximal position. The drug delivery device further comprises a drop lock mechanism comprising a non-blocking state and a blocking state.Type: ApplicationFiled: February 15, 2022Publication date: April 18, 2024Applicant: Novo Nordisk A/SInventors: Bo Kvolsbjerg, Nicolai Michael Villadsen
-
Patent number: 11952574Abstract: Oligonucleotides are provided herein that inhibit TMPRSS6 expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with hepcidin deficiency or suppression.Type: GrantFiled: June 23, 2023Date of Patent: April 9, 2024Assignees: Novo Nordisk A/S, Dicerna Pharmaceuticals, Inc.Inventors: Anna Linda Blois, Christina Marie Priest, Jihye Park, Henryk Dudek
-
Patent number: 11944791Abstract: A multi-use drug delivery device for extended use, wherein the multi-use drug delivery device comprising a multi-use main portion (310) and a single-use flow conducting device (360) adapted for conducting drug to the subcutaneous tissue of a subject, wherein the change from a connected configuration to an unconnected configuration of the main portion and the flow conducting device is through the intermediate configuration. The intermediate configuration comprises an equalizing channel defining an equalizing flow path (304) different from an unintended flow path (303).Type: GrantFiled: August 20, 2018Date of Patent: April 2, 2024Assignee: Novo Nordisk A/SInventors: Henrik Bengtsson, Vera Pinto Glenting, Joern Drustrup, Jonas Kildegaard Pedersen
-
Patent number: 11931556Abstract: The present invention provides a drug injection device (100, 100?, 100?) comprising a first element (130) and a second element (102, 102?, 102?) configured to undergo movement relative to each other corresponding to an action performed on or by the drug injection device (100, 100?, 100?), wherein the first element (130) comprises serially disposed protrusions (133), and wherein the second element (102, 102?, 102?) comprises a second element base and a deflectable transducer (170, 170?, 170?). The deflectable transducer (170, 170?, 170?) defines a base portion attached to the second element base, and a deflectable portion (162) configured for sequentially cooperating with the plurality of protrusions (133), wherein a processor (165) is electrically connected with the deflectable transducer (170, 170?, 170?) to register activation signals.Type: GrantFiled: February 2, 2019Date of Patent: March 19, 2024Assignee: Novo Nordisk A/SInventors: Nikolaj Eusebius Jakobsen, Per Einar Pontus Holm
-
Publication number: 20240066235Abstract: The invention relates to a medical injection device for dispensing substantially equally sized dose volumes of a liquid drug. The injection is driven by a torsion spring which is strained prior to each dose release by rotation of a connector element connecting the torsion spring to the rotational drive structure. The dose release is controlled by an axial movement of the rotational drive structure which can only be moved axially when the connector element has been rotated to a specific rotational position.Type: ApplicationFiled: January 14, 2022Publication date: February 29, 2024Applicant: Novo Nordisk A/SInventor: Nikolaj Eusebius Jakobsen
-
Publication number: 20240067944Abstract: The present invention provides ISVD polypeptide derivatives capable of binding coagulation Factor IX(a) and Factor X(a) which are highly potent and provide a sufficiently long half-life such to allow for effective subcutaneous—as well as peroral administration. The ISVD polypeptides derivatives disclosed herein are thus suitable for treatment of haemophilia A, haemophilia A with inhibitors and acquired haemophilia A by various routes of administration including subcutaneous and peroral administration.Type: ApplicationFiled: July 7, 2023Publication date: February 29, 2024Applicant: Novo Nordisk A/SInventors: Andreas Vegge, Daniele Granata, Eva Johansson, Jais Rose Bjelke, Jacob Lund, Philip Jonas Sassene, Per J. Greisen, Thomas Egebjerg, Evelyn De Tavernier, Soren Steffensen, Marie-Ange Buyse, Frantisek Hubalek, Simone Fulle, Mathias Norrman
-
Patent number: 11912759Abstract: The invention provides antibodies that specifically bind transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.Type: GrantFiled: May 4, 2021Date of Patent: February 27, 2024Assignees: NOVO NORDISK A/S, UNIVERSITY HEALTH NETWORKInventors: Yue Liu, Tarlochan S. Nijjar, Avijit Chakrabartty, Jeffrey N. Higaki
-
Publication number: 20240016896Abstract: The present invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide comprising no more than 0.01% (w/w) phenol, their preparation, kits comprising such compositions as well as uses thereof.Type: ApplicationFiled: July 26, 2023Publication date: January 18, 2024Applicant: Novo Nordisk A/SInventors: Eva Horn Moeller, Michael Duelund Soerensen, Joakim Lundqvist
-
Patent number: 11873332Abstract: The invention provides antibody formulations and methods useful for prophylaxis or treatment of transthyretin-related amyloidosis.Type: GrantFiled: November 28, 2018Date of Patent: January 16, 2024Assignee: NOVO NORDISK A/SInventors: Joseph Alexander Soto, Andrea Hawe, Ruedeeporn Tantipolphan, Stefan Heindl
-
Patent number: 11858992Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.Type: GrantFiled: February 1, 2021Date of Patent: January 2, 2024Assignee: NOVO NORDISK A/SInventors: Vibeke Westphal Stennicke, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune Salbo, Anette Henriksen, Soeren Padkjaer
-
Patent number: 11844787Abstract: This disclosure provides compounds and compositions for activating pyruvate kinase R (PKR) and related methods of manufacturing and using these compounds and compositions.Type: GrantFiled: June 18, 2021Date of Patent: December 19, 2023Assignee: NOVO NORDISK HEALTH CARE AGInventors: Anna Ericsson, Neal Green, Gary Gustafson, David R. Lancia, Jr., Gary Marshall, Lorna Mitchell, David Richard, Zhongguo Wang
-
Patent number: 11840560Abstract: Prodrug compounds of GLP-1/GIP receptor co-agonists are provided wherein the GLP-1/GIP receptor co-agonists have been modified by the linkage of a dipeptide to the GLP-1/GIP receptor co-agonist through an amide bond. The prodrugs disclosed herein have extended half-lives and are converted to the active GLP-1/GIP receptor co-agonist at physiological conditions through a non-enzymatic reaction driven by chemical instability.Type: GrantFiled: January 20, 2023Date of Patent: December 12, 2023Assignee: Novo Nordisk A/SInventors: Patrick James Knerr, Brian Patrick Finan
-
Patent number: 11833248Abstract: The invention relates to pharmaceutical compositions comprising a peptide, such as a GLP-1 peptide and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The invention further relates to processes for the preparation of such compositions, and their use in medicine.Type: GrantFiled: September 13, 2019Date of Patent: December 5, 2023Assignee: Novo Nordisk A/SInventors: Betty Lomstein Pedersen, Birgitte Nissen
-
Patent number: 11827690Abstract: The disclosure provides apolipoprotein C-II (apoC-II) mimetic peptides and methods for treating hypertriglyceridemia in a patient with an effective amount of an apoC-II mimetic peptide.Type: GrantFiled: March 9, 2021Date of Patent: November 28, 2023Assignees: Novo Nordisk Inc., United State of America, As Represented by the Secretary, Dept. of Health and Human ServicesInventors: Alan Thomas Remaley, Soumitra Shanker Ghosh, Madhav N. Devalaraja, Chih-Hung Lo, Denis O. Sviridov, Anna Wolska
-
Patent number: 11787874Abstract: The application relates to unique FX binding molecules, such as antibodies and fragments thereof which are useful in the treatment of haemophilia.Type: GrantFiled: November 15, 2018Date of Patent: October 17, 2023Assignee: Novo Nordisk A/SInventors: Jacob Lund, Karina Thorn, Mikkel Nors Harndahl, Marie-Ange Buyse, Evelyn De Tavernier, Soren Steffensen
-
Patent number: 11787837Abstract: The present invention relates to a novel acylating agent, a method for its preparation, and a method of using it for acylating one or more amino groups of an amino acid, a peptide, or a protein. The novel acylating agent may be a compound which comprises a structural element —HN—(CH2)2-(O—((CH2)2)k-O—(CH2)n-CO—, wherein k is an integer in the range of 1-10, and n is an integer in the range of 1-2, being esterified at its —CO-end to the hydroxy group of 3,5-dichloro-2-hydroxy-benzenesulfonic acid (3,5-DC-2-HBSA). This novel acylating agent has an improved stability. Using this agent the acylation process is improved as regards robustness, as well as improving yield and overall production economy. The novel acylating agent is useful for acylating pharmaceutical peptides and proteins such as GLP-1, insulin, pYY, and amylin. The invention also relates to a number of novel GLP-1 precursor peptides and derivatives in which the two N-terminal amino acids have been deleted.Type: GrantFiled: November 7, 2017Date of Patent: October 17, 2023Assignee: Novo Nordisk A/SInventors: Kim Birkebaek Jensen, Magnus Bernt Fredrik Gustafsson
-
Patent number: 11779648Abstract: Peptide co-agonists of the human GLP-1 and GIP receptors suitable for oral delivery, including long-acting derivatives, and their medical use in treatment and/or prevention of obesity, diabetes, and/or liver diseases are described.Type: GrantFiled: January 12, 2022Date of Patent: October 10, 2023Assignee: Novo Nordisk A/SInventors: Patrick James Knerr, Brian Finan, Richard Dimarchi
-
Anti-ANGPTL3 antibodies suitable for high concentration compositions and subcutaneous administration
Patent number: 11780910Abstract: The present invention relates to novel monovalent anti-ANGPTL3 antibodies for use in medicine and in particular for lowering of plasma triglycerides levels in patients in need thereof, such as patients suffering from or at risk of hypertriglyceridemia and/or cardiovascular disease, such as atherosclerotic cardiovascular disease (ASCVD) as well as pharmaceutical compositions suitable for subcutaneous administration and kits comprising such compounds and compositions.Type: GrantFiled: May 2, 2023Date of Patent: October 10, 2023Assignee: Novo Nordisk A/SInventors: Anette Henriksen, Thomas Nylandsted Krogh, Per J. Greisen, Thomas Egebjerg -
Patent number: 11771829Abstract: Self-righting articles, such as self-righting capsules for administration to a subject, are generally provided. In some embodiments, the self-righting article may be configured such that the article may orient itself relative to a surface (e.g., a surface of a tissue of a subject). The self-righting articles described herein may comprise one or more tissue engaging surfaces configured to engage (e.g., interface with, inject into, anchor) with a surface (e.g., a surface of a tissue of a subject). In some embodiments, the self-righting article may have a particular shape and/or distribution of density (or mass) which, for example, enables the self-righting behavior of the article. In some embodiments, the self-righting article may comprise a tissue interfacing component and/or a pharmaceutical agent (e.g., for delivery of the active pharmaceutical agent to a location internal of the subject) such as a liquid pharmaceutical agent.Type: GrantFiled: January 31, 2020Date of Patent: October 3, 2023Assignees: Massachusetts Institute of Technology, Novo Nordisk A/S, The Brigham and Women's Hospital, Inc.Inventors: Robert S. Langer, Carlo Giovanni Traverso, Alex G. Abramson, Morten Revsgaard Frederiksen, Mikkel Oliver Jespersen, Brian Mouridsen, Jesper Windum, Mette Poulsen, Brian Jensen, Jorrit Jeroen Water, Mikkel Wennemoes Hvitfeld Ley, Xiaoya Lu, Andreas Vegge
-
Publication number: 20230302094Abstract: The present invention relates to improved medical therapies for all forms and stages of dementia involving administration of (i) GLP-1 receptor agonists to subjects with metabolic syndrome or (ii) semaglutide.Type: ApplicationFiled: June 12, 2023Publication date: September 28, 2023Applicant: Novo Nordisk A/SInventors: Sarah Friedrich, Charlotte Christine Thim Hansen, Lotte Bjerre Knudsen, Anna Secher